fenofibrate (Lipidil EZ, etc) for slowing progression of diabetic retinopathy
January 2008
There's interest in using fenofibrate (Lipidil EZ, etc) for slowing progression of diabetic retinopathy.
Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness in adults.
A new subgroup analysis of the FIELD trial shows that type 2 diabetes patients taking fenofibrate are a third less likely to need laser treatment for retinopathy.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive